or Try an Advanced Search...

    Technical Analysis for ELEV - Elevation Oncology, Inc.

    Grade Last Price % Change Price Change
    D 2.86 5.93% 0.16
    ELEV closed up 5.93 percent on Monday, July 1, 2024, on approximately normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Up
    Historical ELEV trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Up 3 Days in a Row Strength 0.00%
    Pocket Pivot Bullish Swing Setup 5.93%
    Volume Surge Other 5.93%
    Wide Bands Range Expansion 5.93%
    Oversold Stochastic Weakness 5.93%
    Slingshot Bearish Bearish Swing Setup 13.94%
    Crossed Above 200 DMA Bullish 13.94%
    Wide Bands Range Expansion 13.94%
    Oversold Stochastic Weakness 13.94%
    Older End-of-Day Signals for ELEV ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 8 hours ago
    Rose Above Previous Day's High about 8 hours ago
    Up 3% about 8 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    Up 2% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ELEV Chart by TradingView
    Basic chart:

    Profile

    Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab

    Is ELEV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
    May 7 Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
    May 3 Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
    May 2 Elevation Oncology files for $350M mixed shelf
    May 2 Elevation Oncology GAAP EPS of -$0.23
    May 2 Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
    Apr 22 Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)
    Apr 11 7 Top Stocks Under $7
    Apr 8 Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
    Mar 7 Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023
    See more ELEV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.8299
    52 Week Low 0.363
    Average Volume 768,933
    200-Day Moving Average 2.40
    50-Day Moving Average 3.48
    20-Day Moving Average 3.08
    10-Day Moving Average 2.63
    Average True Range 0.28
    RSI (14) 41.86
    ADX 31.35
    +DI 17.01
    -DI 29.33
    Chandelier Exit (Long, 3 ATRs) 3.48
    Chandelier Exit (Short, 3 ATRs) 3.07
    Upper Bollinger Bands 4.05
    Lower Bollinger Band 2.11
    Percent B (%b) 0.39
    BandWidth 62.92
    MACD Line -0.31
    MACD Signal Line -0.29
    MACD Histogram -0.0169
    Fundamentals Value
    Market Cap 121.31 Million
    Num Shares 42.4 Million
    EPS -2.03
    Price-to-Earnings (P/E) Ratio -1.41
    Price-to-Sales 0.00
    Price-to-Book 1.97
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.27
    Resistance 3 (R3) 3.23 3.05 3.20
    Resistance 2 (R2) 3.05 2.95 3.07 3.17
    Resistance 1 (R1) 2.96 2.89 3.01 3.00 3.15
    Pivot Point 2.78 2.78 2.81 2.80 2.78
    Support 1 (S1) 2.69 2.68 2.74 2.73 2.57
    Support 2 (S2) 2.51 2.62 2.53 2.55
    Support 3 (S3) 2.42 2.51 2.52
    Support 4 (S4) 2.46